Comparative Pharmacology
Head-to-head clinical analysis: PANMYCIN versus SUMYCIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PANMYCIN versus SUMYCIN.
PANMYCIN vs SUMYCIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Tetracycline antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing aminoacyl-tRNA from attaching to the A site.
Tetracycline antibiotic inhibiting bacterial protein synthesis by binding to the 30S ribosomal subunit, blocking aminoacyl-tRNA binding to the A site.
250-500 mg PO q6h or 500 mg to 1 g IV q6h; maximum 4 g/day
250-500 mg orally every 6 hours or 500 mg orally every 12 hours (maximum 2 g/day)
None Documented
None Documented
Terminal elimination half-life is 6-8 hours in patients with normal renal function. Half-life is significantly prolonged (up to 80 hours) in anuria, requiring dose adjustment.
6-12 hours; prolonged in renal impairment (up to 24-48 hours in anuria)
Primarily renal excretion of unchanged drug via glomerular filtration; 80-90% recovered in urine within 24 hours. Biliary/fecal excretion accounts for <5%.
Renal (60-80% unchanged via glomerular filtration), biliary/fecal (20-40%)
Category C
Category C
Tetracycline Antibiotic
Tetracycline Antibiotic